HK1210721A1 - Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor cdk4/6 braf - Google Patents

Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor cdk4/6 braf

Info

Publication number: HK1210721A1
Authority: HK; Hong Kong
Prior art keywords: cdk4; inhibitor; braf; pharmaceutical combinations; raf
Prior art date: 2012-07-26

Application number

HK15111684.1A

Other languages

English (en)

Chinese (zh)

Inventor

Giordano Caponigro

Darrin Stuart

Sunkyu Kim

Alice Loo

Scott Delach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-26

Filing date

2015-11-27

Publication date

2016-05-06

2015-11-27 Application filed by Novartis Ag filed Critical Novartis Ag

2016-05-06 Publication of HK1210721A1 publication Critical patent/HK1210721A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK15111684.1A 2012-07-26 2015-11-27 Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor cdk4/6 braf HK1210721A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261676134P	2012-07-26	2012-07-26
US201361830911P	2013-06-04	2013-06-04
PCT/US2013/051990 WO2014018725A1 (en)	2012-07-26	2013-07-25	Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor

Publications (1)

Publication Number	Publication Date
HK1210721A1 true HK1210721A1 (en)	2016-05-06

Family

ID=48917729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15111684.1A HK1210721A1 (en)	2012-07-26	2015-11-27	Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor cdk4/6 braf

Country Status (16)

Country	Link
US (1)	US9700557B2 (ja)
EP (1)	EP2877174B1 (ja)
JP (1)	JP6320379B2 (ja)
KR (1)	KR102113363B1 (ja)
CN (1)	CN104507474B (ja)
AR (1)	AR091876A1 (ja)
AU (1)	AU2013295771B2 (ja)
CA (1)	CA2874860C (ja)
ES (1)	ES2778059T3 (ja)
HK (1)	HK1210721A1 (ja)
IN (1)	IN2015DN00376A (ja)
JO (1)	JO3776B1 (ja)
MX (1)	MX360045B (ja)
RU (1)	RU2685250C2 (ja)
TW (1)	TWI599357B (ja)
WO (1)	WO2014018725A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2676177T3 (es) *	2012-12-20	2018-07-17	Novartis Ag	Una combinación farmacéutica que comprende binimetinib
EP3327144B1 (en) *	2013-02-25	2020-03-25	Novartis AG	Novel androgen receptor mutation
BR112015023483B8 (pt) *	2013-03-21	2023-01-31	Novartis Ag	Uso de um inibidor de b-raf e um inibidor de mek 1/2"
CN107205933A (zh) *	2014-12-23	2017-09-26	米伦纽姆医药公司	Raf抑制剂与aurora激酶抑制剂的组合
WO2016155670A1 (zh) *	2015-04-01	2016-10-06	苏州晶云药物科技有限公司	一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN105753869B (zh) *	2015-04-01	2018-09-25	苏州晶云药物科技有限公司	一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2017037574A1 (en) *	2015-08-28	2017-03-09	Novartis Ag	Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
CN105732642B (zh) *	2015-11-18	2018-09-25	苏州晶云药物科技有限公司	一种cdk抑制剂和mek抑制剂的共晶及其制备方法
DK3463345T3 (da) *	2016-06-03	2023-01-09	Array Biopharma Inc	Farmaceutiske kombinationer
WO2018039324A1 (en) *	2016-08-23	2018-03-01	Eisai R&D Management Co., Ltd.	Combination therapies for the treatment of hepatocellular carcinoma
KR102341660B1 (ko) *	2016-09-19	2021-12-23	노파르티스 아게	Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
WO2018081211A1 (en) *	2016-10-26	2018-05-03	Li George Y	Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
US11395821B2 (en)	2017-01-30	2022-07-26	G1 Therapeutics, Inc.	Treatment of EGFR-driven cancer with fewer side effects
KR20240032157A (ko)	2017-05-02	2024-03-08	노파르티스 아게	병용 요법
WO2018218633A1 (en)	2017-06-02	2018-12-06	Beijing Percans Oncology Co. Ltd.	Combination therapies for treating cancers
JP2021509680A (ja)	2018-01-08	2021-04-01	ジー１、セラピューティクス、インコーポレイテッドＧ１Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｇ１ｔ３８の優れた投与レジメン
MA51846A (fr)	2018-02-15	2021-04-21	Nuvation Bio Inc	Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
WO2019195959A1 (en) *	2018-04-08	2019-10-17	Cothera Biosciences, Inc.	Combination therapy for cancers with braf mutation
US11633401B2 (en) *	2018-07-06	2023-04-25	Memorial Sloan Kettering Cancer Center	Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
MX2021007477A (es) *	2018-12-20	2021-08-05	Novartis Ag	Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
TW202114667A (zh) *	2019-09-11	2021-04-16	大陸商江蘇恒瑞醫藥股份有限公司	Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途
MX2022006783A (es)	2019-12-10	2022-07-11	Hoffmann La Roche	Nuevos derivados de metilquinazolinona.
EP4149472A1 (en) *	2020-05-12	2023-03-22	Novartis AG	Therapeutic combinations comprising a craf inhibitor
WO2023230554A1 (en)	2022-05-25	2023-11-30	Pfizer Inc.	Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
PL230179B1 (pl) *	2002-03-13	2018-09-28	Array Biopharma Inc	N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
JP2007530654A (ja)	2004-03-30	2007-11-01	ファイザー・プロダクツ・インク	シグナル伝達阻害剤の組合せ
RU2508110C2 (ru)	2008-07-11	2014-02-27	Новартис Аг	КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
CN103788100A (zh)	2008-08-22	2014-05-14	诺华股份有限公司	作为cdk抑制剂的吡咯并嘧啶化合物
AR077975A1 (es) *	2009-08-28	2011-10-05	Irm Llc	Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP5918214B2 (ja) *	2010-04-13	2016-05-18	ノバルティスアーゲー	がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ

2013
- 2013-07-24 AR ARP130102621A patent/AR091876A1/es not_active Application Discontinuation
- 2013-07-25 TW TW102126726A patent/TWI599357B/zh active
- 2013-07-25 IN IN376DEN2015 patent/IN2015DN00376A/en unknown
- 2013-07-25 CN CN201380039725.5A patent/CN104507474B/zh active Active
- 2013-07-25 JP JP2015524444A patent/JP6320379B2/ja active Active
- 2013-07-25 WO PCT/US2013/051990 patent/WO2014018725A1/en active Application Filing
- 2013-07-25 ES ES13745540T patent/ES2778059T3/es active Active
- 2013-07-25 EP EP13745540.8A patent/EP2877174B1/en active Active
- 2013-07-25 CA CA2874860A patent/CA2874860C/en active Active
- 2013-07-25 AU AU2013295771A patent/AU2013295771B2/en active Active
- 2013-07-25 US US14/414,998 patent/US9700557B2/en active Active
- 2013-07-25 MX MX2015001122A patent/MX360045B/es active IP Right Grant
- 2013-07-25 RU RU2015106524A patent/RU2685250C2/ru active
- 2013-07-25 KR KR1020157001594A patent/KR102113363B1/ko active IP Right Grant
- 2013-07-25 JO JOP/2013/0223A patent/JO3776B1/ar active
2015
- 2015-11-27 HK HK15111684.1A patent/HK1210721A1/xx unknown

Also Published As

Publication number	Publication date
ES2778059T3 (es)	2020-08-07
IN2015DN00376A (ja)	2015-06-12
EP2877174A1 (en)	2015-06-03
US9700557B2 (en)	2017-07-11
KR20150036146A (ko)	2015-04-07
RU2015106524A (ru)	2016-09-20
BR112014033118A2 (pt)	2017-06-27
WO2014018725A1 (en)	2014-01-30
AU2013295771A1 (en)	2014-12-11
EP2877174B1 (en)	2020-01-01
AR091876A1 (es)	2015-03-04
KR102113363B1 (ko)	2020-05-21
CA2874860C (en)	2020-06-23
BR112014033118A8 (pt)	2023-01-31
TW201412316A (zh)	2014-04-01
US20150164897A1 (en)	2015-06-18
MX2015001122A (es)	2015-04-08
CN104507474B (zh)	2018-01-02
AU2013295771B2 (en)	2016-08-11
JP2015523397A (ja)	2015-08-13
MX360045B (es)	2018-10-19
JP6320379B2 (ja)	2018-05-09
CN104507474A (zh)	2015-04-08
CA2874860A1 (en)	2014-01-30
JO3776B1 (ar)	2021-01-31
TWI599357B (zh)	2017-09-21
RU2685250C2 (ru)	2019-04-17

Publication	Publication Date	Title
HK1210721A1 (en)	2016-05-06	Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor cdk4/6 braf
IL274988A (en)	2020-07-30	Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
HRP20180953T1 (hr)	2018-07-27	Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
ZA201303433B (en)	2014-12-23	Inhibitors of hiv replication
PL2909204T3 (pl)	2019-07-31	Inhibitory GSK3 i sposoby ich stosowania
HK1202112A1 (en)	2015-09-18	Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1206264A1 (en)	2016-01-08	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2718283A4 (en)	2014-10-29	INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
HK1212675A1 (zh)	2016-06-17	氨肽酶和腦啡肽酶的混合抑制劑

Legal Events

Date	Code	Title	Description
2021-04-23	CHRG	Changes in the register	Free format text: CORRECTION OF THE NAME OF THE APPLICANT FROM "ARRAY BIOPHARMA, INC." TO "ARRAY BIOPHARMA INC."